Oncternal Therapeutics Inc Revenue Growth Rates (ONCT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Oncternal Therapeutics Inc   (NASDAQ: ONCT)
 

ONCT's Revenue Growth by Quarter and Year

Oncternal Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ONCT Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September 0.49
2nd Quarter June 0.80
1st Quarter March 0.57
FY 1.86

ONCTs Annual Revenue
Oncternal Therapeutics Inc 's Revenue in the fiscal year 2023 $ 0.79 millions
Oncternal Therapeutics Inc 's Revenue in the fiscal year 2022 $ 1.49 millions
Oncternal Therapeutics Inc 's Revenue in the fiscal year 2021 $ 4.32 millions
Oncternal Therapeutics Inc 's Revenue in the fiscal year 2020 $ 3.38 millions
Oncternal Therapeutics Inc 's Revenue in the fiscal year 2019 $ 2.43 millions




ONCT Revenue third quarter 2024 Y/Y Growth Comment
Oncternal Therapeutics Inc achieved in the third quarter 2024, above Company average Revenue surge of 174.44% year on year, to $ 0.49 millions.

Looking into third quarter 2024 results within Major Pharmaceutical Preparations industry 18 other companies have achieved higher Revenue growth. While Oncternal Therapeutics Inc ' s Revenue doubling of 174.44% ranks overall at the positon no. 118 in the third quarter 2024.


ONCT Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - 76.47 % -69.64 % -64.78 %
3rd Quarter September 174.44 % -52.63 % -82.16 % 261.02 %
2nd Quarter June 627.27 % -42.11 % -78.41 % 41.94 %
1st Quarter March 185 % -73.33 % 0 % 29.31 %
FY   - -46.98 % -65.51 % -

Financial Statements
Oncternal Therapeutics Inc 's third quarter 2024 Revenue $ 0.49 millions ONCT's Income Statement
Oncternal Therapeutics Inc 's third quarter 2023 Revenue $ 0.18 millions Quarterly ONCT's Income Statement


ONCT Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - 66.67 % -55.26 % -73.71 %
3rd Quarter September -38.25 % 63.64 % 100 % 142.05 %
2nd Quarter June 40.35 % -45 % -74.67 % 17.33 %
1st Quarter March 90 % 17.65 % 33.93 % -52.83 %
FY (Year on Year)   - -46.98 % -65.51 % -


Back to ONCT Growth rate Comparisons >> Back to ONCT Growth rate Comparisons >>


Revenue third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #19
Healthcare Sector #39
Overall #118

Revenue Y/Y Growth Statistics
High Average Low
655.66 % 54.82 % -82.05 %
(Sep 30 2024)   (Dec. 30, 2015)
Revenue third quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #19
Healthcare Sector #39
Overall #118
Revenue Y/Y Growth Statistics
High Average Low
655.66 % 54.82 % -82.05 %
(Sep 30 2024)   (Dec. 30, 2015)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Oncternal Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
171.62 % 21.92 % -74.4 %
(Dec 31 2020)  


ONCT's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2024 Oncternal Therapeutics Inc disclosed fall in Revenue from the second quarter by -38.25% to $ 0.49 millions, from $ 0.80 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2024 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 208 other companies have achieved higher Revenue quarter on quarter growth. While Oncternal Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3659.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #209
Healthcare Sector #556
Overall #3659
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #209
Healthcare Sector #556
Overall #3659
Revenue Q/Q Growth Statistics
High Average Low
171.62 % 21.92 % -74.4 %
(Dec 31 2020)  


ONCT's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2024 Oncternal Therapeutics Inc disclosed fall in Revenue from the second quarter by -38.25% to $ 0.49 millions, from $ 0.80 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2024 Revenue, this plainly could not be substantial to rescue Major Pharmaceutical Preparations's company achievement, Most analysts pointed out.

Within Major Pharmaceutical Preparations industry 208 other companies have achieved higher Revenue quarter on quarter growth. While Oncternal Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3659.


Oncternal Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)
Cumulative Revenue 12 Months Ending $ 2.16 $ 1.85 $ 1.15 $ 0.78 $ 0.66
Y / Y Revenue Growth (TTM) 227.92 % 114.15 % 21.54 % -47.32 % -64.85 %
Year on Year Revenue Growth Overall Ranking # 3461 # 3483 # 0 # 0 # 2575
Seqeuential Revenue Change (TTM) 17.06 % 60.38 % 46.62 % 19.12 % -23.55 %
Seq. Revenue Growth (TTM) Overall Ranking # 3236 # 2649 # 0 # 0 # 3548


Cumulative Revenue growth Comment
With 227.92% annual Revenue growth, Oncternal Therapeutics Inc would report a record annual Revenue surge if the fiscal year would end on Sep 30 2024.

In the Healthcare sector 501 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3461, from total ranking in previous quarter at 3483.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 159
Healthcare Sector # 502
Overall # 3461

Revenue TTM Y/Y Growth Statistics
High Average Low
227.92 %
 2.32 %
-100 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 159
Sector # 461
S&P 500 # 3236
Cumulative Revenue growth Comment
With 227.92% annual Revenue growth, Oncternal Therapeutics Inc would report a record annual Revenue surge if the fiscal year would end on Sep 30 2024.

In the Healthcare sector 501 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 3461, from total ranking in previous quarter at 3483.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 159
Healthcare Sector # 502
Overall # 3461

Revenue TTM Y/Y Growth Statistics
High Average Low
227.92 %
2.32 %
-100 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 159
Sector # 461
S&P 500 # 3236




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ONCT's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Sep 30 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2024
Regen Biopharma Inc 260.98%$ 260.983 millions
Generation Bio Co 252.00%$ 252.004 millions
Orgenesis Inc 215.45%$ 215.455 millions
Omega Therapeutics Inc 214.32%$ 214.320 millions
Lineage Cell Therapeutics Inc 203.29%$ 203.291 millions
Arvinas Inc 195.95%$ 195.954 millions
Imagenebio Inc 195.36%$ 195.359 millions
Volitionrx Limited187.22%$ 187.222 millions
Proqr Therapeutics N v 183.16%$ 183.160 millions
Oncternal Therapeutics Inc 175.98%$ 175.978 millions
Zivo Bioscience Inc 166.95%$ 166.949 millions
Scpharmaceuticals Inc 164.12%$ 164.120 millions
Dariohealth Corp 163.49%$ 163.487 millions
Kronos Bio Inc 158.45%$ 158.451 millions
Accelerate Diagnostics Inc 157.99%$ 157.995 millions
Recursion Pharmaceuticals Inc 147.62%$ 147.622 millions
Celularity Inc 145.54%$ 145.536 millions
Armata Pharmaceuticals Inc 142.69%$ 142.694 millions
Rosecliff Acquisition Corp I137.59%$ 137.587 millions
Chimerix Inc 136.36%$ 136.364 millions
Orchestra Biomed Holdings Inc 135.56%$ 135.561 millions
Dianthus Therapeutics Inc 135.06%$ 135.065 millions
Vaxart Inc 134.79%$ 134.793 millions
Absci Corp128.63%$ 128.629 millions
Femasys Inc 127.09%$ 127.085 millions
Sensus Healthcare Inc 126.76%$ 126.757 millions
Blueprint Medicines Corporation126.61%$ 126.610 millions
Verve Therapeutics Inc 120.24%$ 120.244 millions
Meiragtx Holdings Plc113.80%$ 113.796 millions
Celldex Therapeutics inc 110.35%$ 110.349 millions


About Oncternal Therapeutics Inc Revenue Growth Rates (ONCT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Oncternal Therapeutics Inc (CIK 1260990).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000950170-24-122383
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Oncternal Therapeutics Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.